BlackRock Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$68.5M	Sell	1,888,452 -4,652,768	-71%	-$186M	0.07%	264
2016 Q3	$301M	Sell	6,541,220 -1,380,961	-17%	-$72.1M	0.31%	80
2016 Q2	$398M	Buy	7,922,181 +1,084,314	+16%	+$57.7M	0.4%	57
2016 Q1	$366M	Sell	6,837,867 -1,213,841	-15%	-$71.2M	0.38%	62
2015 Q4	$529M	Buy	8,051,708 +302,238	+4%	+$18.7M	0.56%	37
2015 Q3	$438M	Sell	7,749,470 -2,691,241	-26%	-$174M	0.47%	44
2015 Q2	$617M	Buy	10,440,711 +605,277	+6%	+$37.3M	0.64%	31
2015 Q1	$613M	Buy	9,835,434 +1,090,929	+12%	+$63.4M	0.63%	30
2014 Q4	$503M	Buy	8,744,505 +2,649,866	+43%	+$148M	0.51%	45
2014 Q3	$328M	Buy	6,094,639 +2,705,336	+80%	+$143M	0.33%	74
2014 Q2	$178M	Buy	3,389,303 +1,447,801	+75%	+$74M	0.17%	143
2014 Q1	$103M	Buy	1,941,502 +699,602	+56%	+$32.3M	0.1%	225
2013 Q4	$49.8M	Sell	1,241,900 -136,676	-10%	-$5.38M	0.05%	347
2013 Q3	$52.1M	Buy	1,378,576 +466,913	+51%	+$18.2M	0.05%	321
2013 Q2	$35.7M	Buy	+911,663	New	+$35.5M	0.04%	383

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

BlackRock Advisors's TEVA Position: Q4 2016 in Review

BlackRock Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 71% in Q4 2016, selling an estimated $186M and leaving 1,888,452 shares worth $68.5M. The position accounts for 0.07% of the portfolio, ranked #264.

BlackRock Advisors first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $617M in Q2 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

BlackRock Advisors held 1,888,452 shares of Teva Pharmaceuticals worth $68.5M as of Q4 2016.
BlackRock Advisors sold 4,652,768 Teva Pharmaceuticals shares in Q4 2016, an estimated $186M.
Teva Pharmaceuticals made up 0.07% of BlackRock Advisors's portfolio in Q4 2016, its #264 holding.
BlackRock Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Teva Pharmaceuticals position peaked at $617M in Q2 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.